Anaplastic glioma: current treatment and management

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2015-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.2015.1042455PMID 25936680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The future of high-grade glioma: Where we are and where are we going

  2015cited by this paper
• Treatment of anaplastic glioma.

  2015influential reference
• Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study

  2015cited by this paper
• Malignant clinical features of anaplastic gliomas without IDH mutation.

  2015cited by this paper
• Clinical impact of molecular biomarkers in gliomas.

  2015influential reference
• Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

  2014influential reference
• Medical management of high-grade astrocytoma: current and emerging therapies.

  2014cited by this paper
• A vaccine targeting mutant IDH1 induces antitumour immunity

  2014cited by this paper
• ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples

  2014influential reference
• Changing incidence and improved survival of gliomas.

  2014cited by this paper
• Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

  2014influential reference
• Molecular biology of high-grade gliomas: what should the clinician know?

  2014influential reference
• Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

  2014influential reference
• Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

  2014influential reference
• Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

  2014cited by this paper
• Update on treatment strategies for anaplastic glioma: a review of literature

  2014influential reference
• Medical therapy of gliomas

  2014influential reference
• IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

  2014cited by this paper
• Oligodendroglial tumors.

  2014influential reference
• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

  2014influential reference
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

  2013influential reference
• Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors

  2013cited by this paper
• MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

  2013cited by this paper
• Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

  2013cited by this paper
• Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

  2013influential reference
• Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide

  2013cited by this paper
• Prediction of Response to Chemotherapy in Anaplastic Glioma: How Many Markers Does It Take?

  2013cited by this paper
• The integrated landscape of driver genomic alterations in glioblastoma

  2013cited by this paper
• ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

  2013influential reference
• Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

  2013influential reference
• Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers

  2013cited by this paper
• Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

  2013cited by this paper
• Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

  2013cited by this paper
• Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors

  2013cited by this paper
• Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

  2013cited by this paper
• TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

  2013cited by this paper
• New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.

  2013cited by this paper
• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

  2013cited by this paper
• IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.

  2013cited by this paper
• An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

  2013cited by this paper
• High-volume centers for pancreatic cancer surgery: Does the media message matter?

  2013cited by this paper
• Prediction of response to chemotherapy in anaplastic glioma: how many markers does it take?

  2013cited by this paper
• A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

  2012cited by this paper
• Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

  2012cited by this paper
• Initial treatment patterns over time for anaplastic oligodendroglial tumors.

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas

  2012cited by this paper
• Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

  2012cited by this paper
• Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

  2012cited by this paper
• Anaplastic gliomas at first recurrence: Outcome analysis.

  2012cited by this paper
• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

  2012cited by this paper
• A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

  2012cited by this paper
• Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

  2012cited by this paper
• CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

  2012cited by this paper
• Anaplastic Glioma

  2012cited by this paper
• Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

  2012cited by this paper
• Bevacizumab for recurrent WHO grade III anaplastic glioma (AG).

  2012cited by this paper
• MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

  2012cited by this paper
• Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.

  2012cited by this paper
• Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

  2012cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012influential reference
• Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

  2011cited by this paper
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

  2011cited by this paper
• Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas

  2011cited by this paper
• International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

  2011cited by this paper
• Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study

  2011cited by this paper
• Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

  2011cited by this paper
• Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

  2011cited by this paper
• Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

  2011cited by this paper
• Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma

  2011cited by this paper
• A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

  2011cited by this paper
• Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma

  2011cited by this paper
• Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

  2011cited by this paper
• Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

  2010influential reference
• Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

  2010cited by this paper
• Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

  2010cited by this paper
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010influential reference
• Abstract 808: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology

  2010cited by this paper
• Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

  2009cited by this paper
• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2009cited by this paper
• Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

  2009cited by this paper
• Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

  2009cited by this paper
• Bevacizumab and irinotecan for recurrent oligodendroglial tumors

  2009cited by this paper
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

  2009cited by this paper
• Bevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma

  2009cited by this paper
• Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

  2009cited by this paper
• Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

  2009cited by this paper
• Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

  2009cited by this paper

• Results of complex treatment of anaplastic glioma

  2023cites this paper
• Application of Enhanced T1WI of MRI Radiomics in Glioma Grading

  2022cites this paper
• TGIF1 overexpression promotes glioma progression and worsens patient prognosis

  2022cites this paper
• Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma

  2021cites this paper
• Systematic review and meta-analysis of arterial spin-labeling imaging to distinguish between glioma recurrence and post-treatment radiation effect.

  2021cites this paper
• Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway

  2020cites this paper
• MiR-330-3p functions as a tumor suppressor that regulates glioma cell proliferation and migration by targeting CELF1

  2020cites this paper
• Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma

  2020cites this paper
• Noninvasively Evaluating the Grading of Glioma by Multiparametric Magnetic Resonance Imaging.

  2020cites this paper
• Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas

  2020cites this paper
• NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance

  2019cites this paper
• Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

  2018cites this paper
• The Current Treatment Approach for Anaplastic Gliomas

  2018influential citation
• Long noncoding RNA LINC01426 promotes glioma progression through PI3K/AKT signaling pathway and serves as a prognostic biomarker.

  2018cites this paper
• Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.

  2018cites this paper
• Current therapeutic approaches to diffuse grade II and III gliomas

  2018cites this paper
• Egyetemi doktori (PhD) értekezés tézisei

  2018cites this paper
• Caracterización del gen Nampt en el proceso de patogénesis tumoral, valoración diagnóstica, pronóstica y como diana terapeútica.

  2017cites this paper
• NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis

  2017cites this paper
• Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies

  2017cites this paper
• Comparison of chemoradiotherapy with radiotherapy alone for “biopsy only” anaplastic astrocytoma

  2017cites this paper
• Dynamic Contrast‐Enhanced MRI in Low‐Grade Versus Anaplastic Oligodendrogliomas

  2016cites this paper
• Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

  2016cites this paper
• CGCG clinical practice guidelines for the management of adult diffuse gliomas.

  2016influential citation
• IDH-1R132H mutation status in diffuse glioma patients: implications for classification

  2016cites this paper